This sensor architecture enables signal amplification for detection of biomarkers and analytes at extremely low concentration
Background Molecular diagnostics increasingly rely on sensitive detection of biomarkers such as nucleic acids, proteins, and cytokines in complex biological samples. Traditional biosensor probes often suffer from signal quenching when fluorescent dyes are positioned on the outer surface of densely packed probes, limiting their sensitivity and reliability. Additionally, conventional probe designs may lack the ability to selectively concentrate target-bound probes, which is critical for enhancing detection signals in low-abundance scenarios. These limitations are particularly problematic in early-stage disease diagnostics, such as viral infections or inflammatory conditions, where biomarker concentrations can be extremely low. There is a pressing need for biosensor technologies that combine high specificity, signal amplification, and spatial control to enable rapid, accurate, and multiplexed detection of diagnostic targets in clinical samples.
Technology Description This technology encompasses a novel class of biosensor probes that integrate metal nanoparticles with surface-modified magnetic nanoparticles and target-specific recognition elements. The magnetic nanoparticles serve dual roles: they enable magnetic concentration of probe-target complexes and act as physical spacers to prevent fluorescence quenching. The metal nanoparticle core is engineered to enhance plasmonic resonance, amplifying both fluorescence and Raman signals from reporter molecules. Recognition receptors are conjugated to the metal surface to selectively bind diagnostic targets. Upon binding, the probes can be magnetically concentrated onto a treated substrate surface, significantly boosting signal intensity while reducing background noise. This architecture supports both fluorescence and Raman-based detection and is compatible with multiplexed assays. The inventors have demonstrated sensitivity down to 25 pg/mL for cytokines and 1 fM for nucleic acids, making it highly suitable for early detection of viral infections, inflammation, and other disease states. The sensor’s modular design allows for rapid adaptation to new targets, offering a powerful alternative to conventional diagnostic assays.
Fig. 1
Benefits
Applications
Status Seeking development partner, commercial partner, licensing. US Patent Application No. 17/697,638